These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. From darkness to light with biomarkers in early clinical trials of cancer drugs. Carden CP; Banerji U; Kaye SB; Workman P; de Bono JS Clin Pharmacol Ther; 2009 Feb; 85(2):131-3. PubMed ID: 19151637 [TBL] [Abstract][Full Text] [Related]
8. Genomics, personalized medicine and cancer practice. Dancey J Clin Biochem; 2012 Apr; 45(6):379-81. PubMed ID: 22424082 [No Abstract] [Full Text] [Related]
9. Biomarkers of clinical trials using molecular inhibitors and radiotherapy: state-of-the-art. Preface. Bristow RG Cancer Metastasis Rev; 2008 Sep; 27(3):337-8. PubMed ID: 18427733 [No Abstract] [Full Text] [Related]
10. [PCR-technology in the diagnosis, prognosis and therapy of oncologic disease]. Vinogradskaia GR; Marinets OV Vopr Onkol; 2001; 47(1):7-17. PubMed ID: 11317541 [No Abstract] [Full Text] [Related]
11. Advances and challenges in the use of biomarkers in clinical trials. Chabner B Clin Adv Hematol Oncol; 2008 Jan; 6(1):42-3. PubMed ID: 18322440 [No Abstract] [Full Text] [Related]
12. Biomarkers as molecular targets of drug interventions. Smith JJ; Dunn BK Semin Oncol Nurs; 2012 May; 28(2):109-15. PubMed ID: 22542318 [TBL] [Abstract][Full Text] [Related]
13. The role of biomarkers in cancer clinical trials. Reid M; Yasko J Semin Oncol Nurs; 2012 May; 28(2):116-21. PubMed ID: 22542319 [TBL] [Abstract][Full Text] [Related]
14. A target or a demi-target. Mok TS Clin Lung Cancer; 2010 May; 11(3):147-8. PubMed ID: 20439189 [No Abstract] [Full Text] [Related]
15. Biology-driven phase II trials: what is the optimal model for molecular selection? Andre F; Delaloge S; Soria JC J Clin Oncol; 2011 Apr; 29(10):1236-8. PubMed ID: 21343554 [No Abstract] [Full Text] [Related]
16. Biomarkers as surrogate endpoints in cancer trials. Dunn BK; Akpa E Semin Oncol Nurs; 2012 May; 28(2):99-108. PubMed ID: 22542317 [TBL] [Abstract][Full Text] [Related]
17. Fluorescence in situ hybridization analysis of biomarkers in cancer. Mark HF Exp Mol Pathol; 1999 Dec; 67(3):131-4. PubMed ID: 10600395 [No Abstract] [Full Text] [Related]
18. 3rd EORTC-NCI International Meeting on Cancer Molecular Markers: From Discovery to Clinical Practice. Taube SE; Gion M; Schilsky RL Expert Rev Mol Diagn; 2004 Jul; 4(4):431-3. PubMed ID: 15225090 [No Abstract] [Full Text] [Related]
19. Missing the mark. Gewin V Nature; 2007 Oct; 449(7164):770-1. PubMed ID: 17968417 [No Abstract] [Full Text] [Related]
20. Implementing precision medicine initiatives in the clinic: a new paradigm in drug development. Hollebecque A; Massard C; Soria JC Curr Opin Oncol; 2014 May; 26(3):340-6. PubMed ID: 24709975 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]